A Boxed Warning has been added to the label for Elranatamab (Elrexfio), effective May 14, 2026. This significant label revision highlights serious safety concerns, specifically Cytokine Release Syndrome (CRS) and Neurotoxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
What this means
The addition of a Boxed Warning to the Elranatamab label signifies that the FDA has identified serious or life-threatening risks associated with the drug that warrant prominent disclosure. For clinicians, this means heightened awareness and potentially specific management strategies are required when prescribing or administering Elranatamab. The warning specifically details risks of Cytokine Release Syndrome (CRS) and Neurotoxicity. Regarding Cytokine Release Syndrome (CRS), the warning explicitly states that it can include life-threatening or fatal reactions in patients receiving Elranatamab. This necessitates vigilant monitoring for signs and symptoms such as fever, hypotension, hypoxia, and organ dysfunction, and prompt intervention according to established guidelines. For Neurotoxicity, which includes Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), clinicians must monitor for neurological signs and symptoms like encephalopathy, headache, confusion, and seizures. Early recognition and management of these severe adverse events are crucial for patient safety. The presence of a Boxed Warning underscores the importance of a comprehensive risk assessment before initiating treatment and continuous monitoring throughout the treatment course with Elranatamab.
Source
The information regarding this label revision was obtained from the U.S. Food and Drug Administration (FDA) via DailyMed. The revised label, featuring the Boxed Warning, became effective on May 14, 2026, and is accessible on dailymed.nlm.nih.gov.